[1]·½ºìÐÇ,ºú×æϼ,ÕÅÌÎ,µÈ.¹ýÃôÐÔ×Ïñ°»¼¶ù¼Ì·¢ÉöË𺦵ÄΣÏÕÒòËØ·ÖÎö[J].ÐÂÏçҽѧԺѧ±¨,2023,40(9):856-859.[doi:10.7683/xxyxyxb.2023.09.010]
¡¡FANG Hongxing,HU Zuxia,ZHANG Tao,et al.Risk factors of secondary renal damage in children with Henoch-Schonlein purpura[J].Journal of Xinxiang Medical University,2023,40(9):856-859.[doi:10.7683/xxyxyxb.2023.09.010]
µã»÷¸´ÖÆ

¹ýÃôÐÔ×Ïñ°»¼¶ù¼Ì·¢ÉöË𺦵ÄΣÏÕÒòËØ·ÖÎö
·ÖÏíµ½£º

¡¶ÐÂÏçҽѧԺѧ±¨¡·[ISSN:1004-7239/CN:41-1186/R]

¾í:
40¾í
ÆÚÊý:
2023Äê9
Ò³Âë:
856-859
À¸Ä¿:
ÁÙ´²Ñо¿
³ö°æÈÕÆÚ:
2023-09-05

ÎÄÕÂÐÅÏ¢/Info

Title:
Risk factors of secondary renal damage in children with Henoch-Schonlein purpura
×÷Õß:
·½ºìÐǺú×æϼÕÅÌÎÄô´ººì
£¨¿ª·âÊжùͯҽԺÉöÔà¿Æ£¬ºÓÄÏ¡¡¿ª·â¡¡475000£©
Author(s):
FANG HongxingHU ZuxiaZHANG TaoNIE Chunhong
£¨Department of Nephrology,Kaifeng Children¡äs Hospital,Kaifeng 475000,Henan Province,China£©
¹Ø¼ü´Ê:
¹ýÃôÐÔ×Ïñ°×Ïñ°ÐÔÉöÑ׶ùͯ
Keywords:
Henoch-Schonlein purpuraHenoch-Schonlein purpura nephritischild
·ÖÀàºÅ:
R725
DOI:
10.7683/xxyxyxb.2023.09.010
ÎÄÏ×±êÖ¾Âë:
A
ÕªÒª:
Ä¿µÄ¡¡Ì½ÌÖ¹ýÃôÐÔ×Ïñ°£¨HSP£©»¼¶ù¼Ì·¢ÉöË𺦵ÄΣÏÕÒòËØ¡£
·½·¨¡¡Ñ¡Ôñ2019Äê8ÔÂÖÁ2022Äê10Ô¿ª·âÊжùͯҽԺÊÕÖεÄ138ÀýHSP»¼¶ùΪÑо¿¶ÔÏ󣬸ù¾ÝÊÇ·ñ¼Ì·¢×Ïñ°ÐÔÉöÑ×£¨HSPN£©·ÖΪHSP×飨n=81£©ºÍHSPN×飨n=57£©¡£»Ø¹ËÐÔ·ÖÎö2×黼¶ùµÄÁÙ´²×ÊÁϼ°ÊµÑéÊÒÖ¸±ê£¬Ó¦ÓöàÒòËØlogistic»Ø¹é·ÖÎöHSPNµÄΣÏÕÒòËØ¡£
½á¹û¡¡138ÀýHSP»¼¶ùÖм̷¢HSPN 57Àý£¬HSPN·¢ÉúÂÊΪ41.30%¡£HSPN×黼¶ùƤÕî³ÖÐøʱ¼ä¡Ý4ÖÜ¡¢Æ¤Õî·´¸´·¢×÷¡¢ÓÐԺǰ¸ÐȾʷ»¼¶ù±ÈÀýÏÔÖø´óÓÚHSP×飨P<0.05£©£»2×黼¶ùµÄÐÔ±ð¡¢ÄêÁä¡¢·¢²¡¼¾½Ú·Ö²¼µÈ±È½Ï²îÒìÎÞͳ¼ÆѧÒâÒ壨P>0.05£©¡£HSPN×黼¶ùѪС°å£¨PLT£©¡¢D-¶þ¾ÛÌ壨D-D£©¡¢°×ϸ°û£¨WBC£©¼ÆÊýˮƽÏÔÖø¸ßÓÚHSP×飬ѪÇåάÉúËØC£¨VitC£©Ë®Æ½ÏÔÖøµÍÓÚHSP×飨P<0.05£©£»2×黼¶ùµÄѪºìµ°°×£¨Hb£©¡¢¸ßÃܶÈÖ¬µ°°×¡¢µÍÃܶÈÖ¬µ°°×¡¢×ܵ¨¹Ì´¼Ë®Æ½±È½Ï²îÒìÎÞͳ¼ÆѧÒâÒ壨P>0.05£©¡£Logistic»Ø¹é·ÖÎö½á¹ûÏÔʾ£¬Æ¤Õî³ÖÐøʱ¼ä¡Ý4ÖÜ¡¢ÓÐԺǰ¸ÐȾʷÒÔ¼°PLT¡¢D-D¡¢WBC¼ÆÊýˮƽÉý¸ßºÍѪÇåVitCˮƽ½µµÍÊÇÓÕ·¢HSPNµÄ¶ÀÁ¢Î£ÏÕÒòËØ£¨P<0.05£©¡£
½áÂÛ¡¡HSP»¼¶ù¼Ì·¢ÉöË𺦵ķçÏսϸߣ¬ÓÐԺǰ¸ÐȾ²¡Ê·¡¢Æ¤Õî³ÖÐøʱ¼ä¡Ý4ÖÜÒÔ¼°PLT¡¢D-D¡¢WBC¼ÆÊýˮƽÉý¸ßºÍѪÇåVitCˮƽ½µµÍÓëHSPNµÄ·¢ÉúÃÜÇÐÏà¹Ø¡£
Abstract:
Objective¡¡To investigate the risk factors of secondary renal damage in children with Henoch-Schonlein purpura (HSP).
Methods¡¡A total of 138 children with HSP admitted to Kaifeng Children¡äs Hospital from August 2019 to October 2022 were selected as the study subjects,and they were divided into HSP group (n=81) and HSPN group (n=57) according to whether they had secondary Henoch-Schonlein purpura nephritis (HSPN).The clinical data and laboratory indicators of the children between the two groups were retrospectively analyzed,and the risk factors of HSPN were analyzed by logistic regression.
Results¡¡ Among the 138 children with HSP,57 cases had secondary HSPN,the incidence rate of HSPN was 41.30%.The proportion of children with rash onset time¡Ý4 weeks,recurrent rash episodes,and pre-hospital infection in the HSPN group were significantly higher than those in the HSP group (P<0.05);there was no statistically significant difference in gender,age,and seasonal distribution of onset of children between the two groups (P>0.05).The levels of platelet (PLT),D-dimer (D-D) and white blood cell (WBC) count of children in the HSPN group were significantly higher than those in the HSP group,and the level of vitamin C (VitC) in serum was significantly lower than that in the HSP group (P<0.05);there was no significant difference in hemoglobin,high-density lipoprotein,low-density lipoprotein and total cholesterol of children between the two groups (P>0.05).The results of logistic regression analysis showed that rash duration¡Ý4 weeks,pre-hospital infection,elevated PLT,D-D and WBC count levels,and decreased serum VitC level were the independent risk factors for HSPN (P<0.05).
Conclusion¡¡Children with HSP have a higher risk of secondary renal damage.Pre-hospital infection,rash duration¡Ý4 weeks,elevated PLT,D-D and WBC levels,and decreased serum VitC level are closely related to the occurrence of HSPN.

²Î¿¼ÎÄÏ×/References:

£Û1£Ý¡¡JELUSIC M,SESTAN M.IgA vasculitis or Henoch-Sch¢‰nlein purpura:genetics and beyond£ÛJ£Ý.Pediatr Nephrol,2021,36(8):2149-2153.
£Û2£Ý¡¡JANG H M,BAEK H,HAN M H,et al.Activation of complement system in Henoch-Sch¢‰nlein purpura nephritis£ÛJ£Ý.Fetal Pediatr Pathol,2022,41(1):29-36.
£Û3£Ý¡¡LEUNG A K C,BARANKIN B,LEONG K F.Henoch-Sch¢‰nlein purpura in children:an updated review£ÛJ£Ý.Curr Pediatr Rev,2020,16(4):265-276.
£Û4£Ý¡¡KURT-ÿðþ‰C ¦aK¦aR E D,SEKAR T,TULLUS K.Biopsy-proven Henoch-Sch¢‰nlein purpura nephritis:a single center experience£ÛJ£Ý.Pediatr Nephrol,2021,36(5):1207-1215.
£Û5£Ý¡¡ºúÑÇÃÀ,½­ÔØ·¼.ÖÌÄʵÓöù¿Æѧ£ÛM£Ý.7°æ.±±¾©:ÈËÃñÎÀÉú³ö°æÉç,2005:1190-1200.
HU Y M,JIANG Z F.Zhu Futang practical pediatrics£ÛM£Ý.7th ed.Beijing:People¡äs Medical Publishing House,2005:1190-1200.
£Û6£Ý¡¡ÖлªÒ½Ñ§»á¶ù¿Æѧ·Ö»áÉöÔàѧ×é.×Ïñ°ÐÔÉöÑ×ÕïÖÎÑ­Ö¤Ö¸ÄÏ(2016)£ÛJ£Ý.Öлª¶ù¿ÆÔÓÖ¾,2017,55(9):647-651.
THE SUBSPECIALTY GROUP OF RENAL DISEASES,THE SOCIETY OF PEDIATRICS,CHINESE MEDICAL ASSOCIATION.Evidence-based guidelines for diagnosis and treatment of Henoch-Schonlein purpura nephritis (2016)£ÛJ£Ý.Chin J Pediatr,2017,55(9):647-651.
£Û7£Ý¡¡DELBET J D,PARMENTIER C,HERBEZ REA C,et al.Management of IgA vasculitis with nephritis£ÛJ£Ý.Paediatr Drugs,2021,23(5):425-435.
£Û8£Ý¡¡HASTINGS M C,RIZK D V,KIRYLUK K,et al.IgA vasculitis with nephritis:update of pathogenesis with clinical implications£ÛJ£Ý.Pediatr Nephrol,2022,37(4):719-733.
£Û9£Ý¡¡KIM W K,KIM C J,YANG E M.Risk factors for renal involvement in Henoch-Sch¢‰nlein purpura£ÛJ£Ý.J Pediatr (Rio J),2021,97(6):646-650.
£Û10£Ý¡¡LIU C,LUO L,FU M,et al.Analysis of children with Henoch-Schonlein purpura secondary to infection£ÛJ£Ý.Clin Rheumatol,2022,41(3):803-810.
£Û11£Ý¡¡SONG Y R,GUO W L,SHENG M,et al.Risk factors associated with renal crescentic formation in pediatric Henoch-Sch¢‰nlein purpura nephritis:a retrospective cohort study£ÛJ£Ý.BMC Pediatr,2020,20(1):501.
£Û12£Ý¡¡SU Q,JIANG L,CHAI J,et al.Changes of peripheral blood lymphocyte subsets and immune function in children with Henoch-Schonlein purpura nephritis£ÛJ£Ý.Iran J Immunol,2021,18(3):259- 267.
£Û13£Ý¡¡WU H,ZHANG P,LU M,et al.Henoch-Sch¢‰nlein purpura nephritis and cerebral venous sinus thrombosis due to hereditary deficiency of antithrombin III£ÛJ£Ý.Indian J Pediatr,2020,87(2):163-164.
£Û14£Ý¡¡DEMIR S,KAPLAN O,CELEBIER M,et al.Predictive biomarkers of IgA vasculitis with nephritis by metabolomic analysis£ÛJ£Ý.Semin Arthritis Rheum,2020,50(6):1238-1244.
£Û15£Ý¡¡À,Ðì´ïÁ¼,ÖìÓ±.¶ùͯ¹ýÃôÐÔ×Ïñ°ÐÔÉöÑײ¡ÀíÌص㼰¢òb¼¶ÒÔÉÏΣÏÕÒòËØ·ÖÎö£ÛJ£Ý.°²»ÕÒ½Ò©,2022,26(5):895-899.
LI J,XU D L,ZHU Y.Pathological characteristics of children with Henoch-Schonlein purpura nephritis and analysis of risk factors above grade ¢òb£ÛJ£Ý.J Anhui Med,2019,26(5):895-899.
£Û16£Ý¡¡TAKISAWA S,TAKINO Y,LEE J,et al.Vitamin C is essential for the maintenance of skeletal muscle functions£ÛJ£Ý.Biology (Basel),2022,11(7):955.
£Û17£Ý¡¡ROGERS D R,LAWLOR D J,MOELLER J L.Vitamin C supplementation and athletic performance:a review£ÛJ£Ý.Curr Sports Med Rep,2023,22(7):255-259.
£Û18£Ý¡¡è¢À°ºì,ÕÔÀöÔÆ,·¿ºìÜ¿,µÈ.2016-2017ÄêÖйú12¡«17Ëê¶ùͯÇàÉÙÄêÉÅʳ΢Á¿ÓªÑøËØÉãÈë×´¿ö£ÛJ£Ý.ÎÀÉúÑо¿,2022,51(4):544-549.
JU L H,ZHAO L Y,FANG H Y,et al.Status of dietary micronutrient intakes among the children of 12-17 years old in China from 2016 to 2017£ÛJ£Ý.J Health Res,2022,51(4):544-549.
£Û19£Ý¡¡ÖìèñÓî,ÂÞåûåû,Ô¬Óñ·¼.Ë«à×´ïĪƬÁªºÏάÉúËØCÖÎÁÆС¶ù¹ýÃôÐÔ×Ïñ°¶ÔѪÇåTM¡¢PTX3¡¢IL-23µÄ±ä»¯Ñо¿£ÛJ£Ý.ºþÄÏʦ·¶´óѧѧ±¨(ҽѧ°æ),2022,19(1):118-121.
ZHU Y Y,LUO Y Y,YUAN Y F.Effect of dipyridamole tablets combined with vitamin C on serum TM,PTX3,IL-23 in children with Henoch-Schonlein purpura£ÛJ£Ý.J Hunan Normal Univ (Med Ed),2022,19(1):118-121.

ÏàËÆÎÄÏ×/References:

[1]¹ù×Óµî.С¼ÁÁ¿¸ÎËØÁªºÏ¼×ÇèßäëÒÖÎÁƹýÃôÐÔ×Ïñ°56 Àý[J].ÐÂÏçҽѧԺѧ±¨,2003,20(06):430.
[2]¹ù×Óµî.С¼ÁÁ¿¸ÎËØÁªºÏ¼×ÇèßäëÒÖÎÁƹýÃôÐÔ×Ïñ°56Àý[J].ÐÂÏçҽѧԺѧ±¨,2003,20(06):430.
[3]À÷ºé½­,ÕÅÓ­»Ô,Áõ´ä»ª,µÈ.Ѫ½¬Ñª¹ÜÄÚƤÉú³¤Òò×Ó¡¢Äò΢Á¿°×µ°°×¼°β2-΢Çòµ°°×Óë¹ýÃôÐÔ×Ïñ°»¼¶ùÔçÆÚÉöËðÉ˵ÄÏà¹ØÐÔ[J].ÐÂÏçҽѧԺѧ±¨,2008,25(02):173.
[4]ÅËЦÔÃ,Ñî´ïʤ,ÕԵ°²,µÈ. ¶ùͯ×Ïñ°ÐÔÉöÑ×Á÷Ðв¡Ñ§¡¢·¢²¡»úÖƼ°Ïà¹ØÉúÎïѧָ±êÑо¿½øÕ¹ [J].ÐÂÏçҽѧԺѧ±¨,2015,32(04):364.[doi:10.7683/xxyxyxb.2015.04.022]
[5]Ê·ÑóÑó,±ÏÁèÔÆ,Ñî´ïʤ.¶ùͯ×Ïñ°ÐÔÉöÑ׺ÍIgAÉö²¡µÄ·¢²¡»úÖƼ°²¡Àí·ÖÐÍÑо¿½øÕ¹[J].ÐÂÏçҽѧԺѧ±¨,2021,38(4):386.[doi:10.7683/xxyxyxb.2021.04.020]
[6]¹ùÇìÒú,¶¡¡¡Ó£,¹ù¡¡æÃ,µÈ.¶ùͯ¹ÂÁ¢ÐÔѪÄòÐÍ×Ïñ°ÐÔÉöÑ×135ÀýÁÙ´²·ÖÎö[J].ÐÂÏçҽѧԺѧ±¨,2018,35(6):531.[doi:10.7683/xxyxyxb.2018.06.021]
¡¡GUO Qing-yin,DING Ying,GUO Ting,et al.Analysis of the clinical features of isolated hematuria Henoch-Schonlein purpura nephritis of children in 135 cases[J].Journal of Xinxiang Medical University,2018,35(9):531.[doi:10.7683/xxyxyxb.2018.06.021]
[7]ÕÅÑÞÃô,ËÎÏþÏè,·âÆ仪.Ëû¿ËĪ˾ÖÎÁƶùͯ×Ïñ°ÐÔÉöÑ×ÁÆЧ¹Û²ì[J].ÐÂÏçҽѧԺѧ±¨,2017,34(9):815.[doi:10.7683/xxyxyxb.2017.09.009]
¡¡ZHANG Yan-min,SONG Xiao-xiang,FENG Qi-hua.Clinical effect of tacrolimus for Henoch-Sch¢‰nlein purpura nephritis in children[J].Journal of Xinxiang Medical University,2017,34(9):815.[doi:10.7683/xxyxyxb.2017.09.009]
[8]ÍõÀöÄÈ,·ëºìÑà,ÕÔ¡¡¼Ñ,µÈ.»ùÓÚÈýάÖÊÁ¿½á¹¹Ä£Ê½ÀíÂÛΪ¿ò¼ÜµÄÔºÍâÑÓÐøÐÔ»¤Àí¸ÉÔ¤¶Ô¹ýÃôÐÔ×Ïñ°»¼¶ù×ñÒ½ÐÐΪ¼°»¤ÀíÂúÒâ¶ÈµÄÓ°Ïì[J].ÐÂÏçҽѧԺѧ±¨,2017,34(10):949.[doi:10.7683/xxyxyxb.2017.10.022]
¡¡WANG Li-na,FENG Hong-yan,ZHAO Jia,et al.Effect of outside hospital continuing nursing intervention based on three-dimensional quality structure on compliance behavior and nursing satisfaction of children with henoch-schonlein purpura[J].Journal of Xinxiang Medical University,2017,34(9):949.[doi:10.7683/xxyxyxb.2017.10.022]

¸üÐÂÈÕÆÚ/Last Update: 2023-09-05